Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MLNT

Melinta Therapeutics (MLNT) Stock Price, News & Analysis

Melinta Therapeutics logo

About Melinta Therapeutics Stock (NASDAQ:MLNT)

Key Stats

Today's Range
N/A
50-Day Range
$0.35
$0.50
52-Week Range
N/A
Volume
N/A
Average Volume
713,628 shs
Market Capitalization
$6.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

Receive MLNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLNT Stock News Headlines

My #1 Pre IPO Trade for 2025 – NAME and TICKER
One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...
SWTX SpringWorks Therapeutics, Inc.
See More Headlines

MLNT Stock Analysis - Frequently Asked Questions

Melinta Therapeutics Inc (NASDAQ:MLNT) posted its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by $13.12. The biotechnology company had revenue of $15.87 million for the quarter, compared to analyst estimates of $15.51 million. Melinta Therapeutics had a negative trailing twelve-month return on equity of 101.29% and a negative net margin of 393.39%.

Melinta Therapeutics's stock reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/12/2019
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MLNT
CUSIP
15130J10
Fax
N/A
Employees
290
Year Founded
N/A

Profitability

Net Income
$-157,190,000.00
Net Margins
-393.39%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$96.43 million
Book Value
$16.96 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.88 million
Optionable
Optionable
Beta
4.16
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:MLNT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners